Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
about
Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma.Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment.The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified NeuroblastomaSystematic identification of non-coding pharmacogenomic landscape in cancer
P2860
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
@en
type
label
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
@en
prefLabel
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
@en
P2093
P1433
P1476
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
@en
P2093
Ana S Leal
Charlotte R Williams
Darlene B Royce
Michael B Sporn
Patricia A Pioli
P356
10.1016/J.CANLET.2017.02.021
P407
P50
P577
2017-02-27T00:00:00Z